{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:57:40Z","timestamp":1792799860350,"version":"4.5.0"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Fibroblast Growth Factor 23 (FGF23) is a bone-derived hormone regulating phosphate and vitamin D metabolism, now recognized as a dynamic biomarker across acute and chronic kidney disorders. Elevated FGF23 is a hallmark of chronic kidney disease (CKD), but also rises acutely in acute kidney injury (AKI) and appears disproportionately high in autosomal dominant polycystic kidney disease (ADPKD), underscoring condition-specific regulation. This review explores the correlation and heterogeneity of FGF23 expression in AKI, CKD, and ADPKD, highlighting shared and divergent mechanisms and the diagnostic and therapeutic implications. We summarize FGF23 expression kinetics in each condition, elucidate known and proposed molecular drivers of its elevation, and discuss how FGF23 serves as a unifying yet disease-divergent marker in renal pathology. In AKI, inflammation, ischemia, and acute metabolic stress drive a rapid FGF23 surge, whereas in CKD, phosphate retention and Klotho deficiency promote a sustained, maladaptive FGF23 elevation. ADPKD shows early FGF23 increases independent of glomerular filtration rate (GFR), potentially due to ectopic production (liver and cysts) and unique tubular defects. Clinically, FGF23 has emerged as an indicator of disease severity and outcomes in these contexts: it can signal early AKI and predict progression, is a strong prognostic factor for mortality and cardiovascular complications in CKD, and correlates with cystic disease burden and kidney growth in ADPKD. We also examine FGF23\u2019s systemic effects (notably on cardiovascular remodeling) and potential therapeutic targets, from modulating phosphate balance and iron metabolism to novel interventions in development. Understanding the nuanced regulation of FGF23 across acute injury, chronic degeneration, and genetic kidney disease provides insight into acute-chronic disease intersections and guides precision diagnostics and therapies for improved patient outcomes.<\/jats:p>","DOI":"10.3389\/fmolb.2026.1764206","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:33:20Z","timestamp":1771310000000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Heterogeneous regulation of fibroblast growth factor 23 in acute kidney injury, chronic kidney disease, and polycystic kidney disease: mechanisms, diagnostic utility, and clinical implications"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaohua","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Nephrology, Zhabei Central Hospital of Jing\u2019an District","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Naval Medical Center, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Zhabei Central Hospital of Jing\u2019an District","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zhabei Central Hospital of Jing\u2019an District","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanmei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Naval Medical Center, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zhabei Central Hospital of Jing\u2019an District","place":["Shanghai, China"]},{"name":"Department of Nephrology, Shanghai Changzheng Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/mnh.0000000000000797","article-title":"Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics","volume":"31","author":"Agoro","year":"2022","journal-title":"Curr. Opinion Nephrology Hypertension"},{"key":"B2","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/nep.12862","article-title":"Fibroblast growth factor 23 and soluble klotho in patients with autosomal dominant polycystic kidney disease","volume":"22","author":"Akiyama","year":"2017","journal-title":"Nephrol. Carlt. Vic."},{"key":"B3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","article-title":"Regulation of phosphate homeostasis by pth, vitamin D, and Fgf23","volume":"61","author":"Bergwitz","year":"2010","journal-title":"Annu. Review Medicine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1210\/jc.2018-00123","article-title":"Hepatic production of fibroblast growth factor 23 in autosomal dominant polycystic kidney disease","volume":"103","author":"Bienaim\u00e9","year":"2018","journal-title":"J. Clinical Endocrinology Metabolism"},{"key":"B5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.semnephrol.2014.09.008","article-title":"Adynamic bone disease: from bone to vessels in chronic kidney disease","volume":"34","author":"Bover","year":"2014","journal-title":"Seminars Nephrology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2215\/cjn.12821216","article-title":"Fibroblast growth factor 23 and kidney disease progression in autosomal dominant polycystic kidney disease","volume":"12","author":"Chonchol","year":"2017","journal-title":"Clin. Journal Am. Soc. Nephrol. CJASN"},{"key":"B7","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/ki.2013.150","article-title":"Plasma Fgf23 levels increase rapidly after acute kidney injury","volume":"84","author":"Christov","year":"2013","journal-title":"Kidney International"},{"key":"B8","doi-asserted-by":"publisher","first-page":"9795","DOI":"10.1074\/jbc.M113.527150","article-title":"Fgf-23 is a negative regulator of prenatal and postnatal erythropoiesis","volume":"289","author":"Coe","year":"2014","journal-title":"J. Biological Chemistry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/mnh.0000000000000614","article-title":"Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease","volume":"29","author":"Courbon","year":"2020","journal-title":"Curr. Opinion Nephrology Hypertension"},{"key":"B10","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1053\/j.ajkd.2013.02.379","article-title":"Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis","volume":"62","author":"Cozzolino","year":"2013","journal-title":"Am. Journal Kidney Diseases The Official Journal Natl. Kidney Found."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174195","article-title":"The role of fibroblast growth factor 23 in inflammation and anemia","volume":"20","author":"Czaya","year":"2019","journal-title":"Int. Journal Molecular Sciences"},{"key":"B12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1440-1797.2011.01443.x","article-title":"Fibroblast growth factor 23 in chronic kidney disease: new insights and clinical implications","volume":"16","author":"Damasiewicz","year":"2011","journal-title":"Nephrol. Carlt. Vic."},{"key":"B13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney International"},{"key":"B14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12967-019-1875-6","article-title":"Fibroblast growth factor 23, endothelium biomarkers and acute kidney injury in critically-ill patients","volume":"17","author":"de Oliveira Neves","year":"2019","journal-title":"J. Translational Medicine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.kint.2018.02.026","article-title":"Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease","volume":"94","author":"Durlacher-Betzer","year":"2018","journal-title":"Kidney International"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"Fgf23 at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat. Reviews Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ekir.2021.01.004","article-title":"Prognostic value of fibroblast growth factor 23 in autosomal dominant polycystic kidney disease","volume":"6","author":"El","year":"2021","journal-title":"Kidney International Reports"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/jci46122","article-title":"Fgf23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J. Clinical Investigation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/cells12040609","article-title":"Fgf23 in chronic kidney disease: bridging the heart and anemia","volume":"12","author":"Rroji","year":"2023","journal-title":"Cells"},{"key":"B20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.kint.2020.07.041","article-title":"Mineral bone disease in autosomal dominant polycystic kidney disease","volume":"99","author":"Gitomer","year":"2021","journal-title":"Kidney International"},{"key":"B21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12882-025-03960-4","article-title":"Commentary: tolvaptan for autosomal dominant polycystic kidney disease (Adpkd) - an update","volume":"26","author":"Gittus","year":"2025","journal-title":"BMC Nephrology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1038\/s41598-017-02068-6","article-title":"Fgf23\/Fgfr4-Mediated left ventricular hypertrophy is reversible","volume":"7","author":"Grabner","year":"2017","journal-title":"Sci. Reports"},{"key":"B23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1681\/asn.0000000000000291","article-title":"Phosphate restriction prevents metabolic acidosis and curbs rise in Fgf23 and mortality in murine folic acid-induced aki","volume":"35","author":"Hamid","year":"2024","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"B24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00467-015-3257-5","article-title":"Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients","volume":"31","author":"Hanudel","year":"2016","journal-title":"Pediatr. Nephrology Berl. Ger."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.ekir.2019.08.010","article-title":"Erythropoietin and fibroblast growth factor 23 in autosomal dominant polycystic kidney disease patients","volume":"4","author":"Hanudel","year":"","journal-title":"Kidney International Reports"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/ndt\/gfy189","article-title":"Effects of erythropoietin on fibroblast growth factor 23 in mice and humans","volume":"34","author":"Hanudel","year":"","journal-title":"Nephrology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0222065","DOI":"10.1371\/journal.pone.0222065","article-title":"Plasma total fibroblast growth factor 23 levels are associated with acute kidney injury and mortality in children with acute respiratory distress syndrome","volume":"14","author":"Hanudel","year":"","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/ki.2010.328","article-title":"Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective","volume":"78","author":"Hu","year":"2010","journal-title":"Kidney International"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.kint.2016.10.034","article-title":"Recombinant \u0391-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy","volume":"91","author":"Hu","year":"2017","journal-title":"Kidney International"},{"key":"B30","doi-asserted-by":"publisher","first-page":"154435","DOI":"10.1016\/j.metabol.2020.154435","article-title":"Roles for fibroblast growth Factor-23 and \u0391-Klotho in acute kidney injury","volume":"116","author":"Hu","year":"2021","journal-title":"Metabolism Clinical Experimental"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1681\/asn.2015111266","article-title":"Chronic hyperphosphatemia and vascular calcification are reduced by stable delivery of soluble klotho","volume":"28","author":"Hum","year":"2017","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"","journal-title":"Kidney International"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"","journal-title":"Jama"},{"key":"B34","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/ndt\/gfp699","article-title":"Fibroblast growth Factor-23 and early decrements in kidney function: the heart and soul study","volume":"25","author":"Ix","year":"2010","journal-title":"Nephrol. Dialysis, Transplantation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1093\/ndt\/gfp191","article-title":"High levels of serum fibroblast growth factor (Fgf)-23 are associated with increased mortality in long haemodialysis patients","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol. Dialysis, Transplantation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1681\/asn.2010121224","article-title":"Fgf-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick","year":"2011","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"B37","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/ndt\/gfr384","article-title":"Cinacalcet treatment and serum Fgf23 levels in haemodialysis patients with secondary hyperparathyroidism","volume":"27","author":"Koizumi","year":"2012","journal-title":"Nephrol. Dialysis, Transplantation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10157-023-02336-y","article-title":"Roles of pth and Fgf23 in kidney failure: a focus on nonclassical effects","volume":"27","author":"Komaba","year":"2023","journal-title":"Clin. Experimental Nephrology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3265\/Nefrologia.2009.29.5.5400.en.full","article-title":"Fgf23: a key player in mineral and bone disorder in ckd","volume":"29","author":"Komaba","year":"2009","journal-title":"Nefrol. publicacion Of. la Soc. Espanola Nefrol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000870","article-title":"Fibroblast growth factor 23, urinary phosphate, and risk of progression of chronic kidney disease","author":"Kosugi","year":"2025","journal-title":"Clin. Journal Am. Soc. Nephrol. CJASN"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1093\/ndt\/gfp682","article-title":"Elevated Fgf-23 in a patient with rhabdomyolysis-induced acute kidney injury","volume":"25","author":"Leaf","year":"2010","journal-title":"Nephrology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.kint.2015.12.035","article-title":"Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery","volume":"89","author":"Leaf","year":"2016","journal-title":"Kidney International"},{"key":"B43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2215\/cjn.10810917","article-title":"Fibroblast growth factor 23 associates with death in critically ill patients","volume":"13","author":"Leaf","year":"2018","journal-title":"Clin. Journal Am. Soc. Nephrol. CJASN"},{"key":"B44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000452880","article-title":"Klotho\/Fgf23 axis in chronic kidney disease and cardiovascular disease","volume":"3","author":"Lu","year":"2017","journal-title":"Kidney Diseases Basel, Switz."},{"key":"B45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12882-023-03125-1","article-title":"A potential link between fibroblast growth Factor-23 and the progression of aki to ckd","volume":"24","author":"Lu","year":"2023","journal-title":"BMC Nephrology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ki.2015.231","article-title":"Key role of the kidney in the regulation of fibroblast growth factor 23","volume":"88","author":"Mace","year":"2015","journal-title":"Kidney International"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094875","article-title":"Non-classical effects of Fgf23: molecular and clinical features","volume":"25","author":"Mart\u00ednez-Heredia","year":"2024","journal-title":"Int. Journal Molecular Sciences"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/ckj\/sfad093","article-title":"Is there a role in acute kidney injury for Fgf23 and klotho?","volume":"16","author":"Mattinzoli","year":"2023","journal-title":"Clin. Kidney Journal"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s00467-012-2384-5","article-title":"From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease","volume":"28","author":"Mekahli","year":"2013","journal-title":"Pediatr. Nephrology Berl. Ger."},{"key":"B50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/circulationaha.114.013876","article-title":"Cinacalcet, fibroblast growth Factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet Hcl therapy to lower cardiovascular events (Evolve) trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-981-10-2041-4_4","article-title":"Inflammation and fibrosis in adpkd","volume":"933","author":"Mun","year":"2016","journal-title":"Adv. Experimental Medicine Biology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2215\/cjn.13281211","article-title":"Fibroblast growth factor 23 and inflammation in ckd","volume":"7","author":"Munoz Mendoza","year":"2012","journal-title":"Clin. Journal Am. Soc. Nephrol. CJASN"},{"key":"B53","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3803\/EnM.2024.1978","article-title":"Roles of parathyroid hormone and fibroblast growth factor 23 in advanced chronic kidney disease","volume":"39","author":"Nakagawa","year":"2024","journal-title":"Endocrinol. Metabolism (Seoul, Korea)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e14434","DOI":"10.14814\/phy2.14434","article-title":"Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (Hif-Phdi) lowers Fgf23 in a model of chronic kidney disease (Ckd)","volume":"8","author":"Noonan","year":"2020","journal-title":"Physiol. Reports"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/j.1523-1755.2004.00465.x","article-title":"Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease","volume":"65","author":"Oberg","year":"2004","journal-title":"Kidney International"},{"key":"B56","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/MNH.0b013e32835421f6","article-title":"Bone disease in ckd","volume":"21","author":"Ott","year":"2012","journal-title":"Curr. Opinion Nephrology Hypertension"},{"key":"B57","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/ki.2010.375","article-title":"Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate","volume":"79","author":"Pavik","year":"2011","journal-title":"Kidney International"},{"key":"B58","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2215\/cjn.09020911","article-title":"Soluble klotho and autosomal dominant polycystic kidney disease","volume":"7","author":"Pavik","year":"2012","journal-title":"Clin. Journal Am. Soc. Nephrol. CJASN"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.bone.2009.08.008","article-title":"Patterns of Fgf-23, Dmp1, and mepe expression in patients with chronic kidney disease","volume":"45","author":"Pereira","year":"2009","journal-title":"Bone"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e2022841118","DOI":"10.1073\/pnas.2022841118","article-title":"Orphan nuclear receptor Err-\u0393 regulates hepatic Fgf23 production in acute kidney injury","volume":"118","author":"Radhakrishnan","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.3390\/ijms25052554","article-title":"Autosomal dominant polycystic kidney disease: extrarenal involvement","volume":"25","author":"Righini","year":"2024","journal-title":"Int. Journal Molecular Sciences"},{"key":"B62","doi-asserted-by":"publisher","first-page":"i46","DOI":"10.1093\/ckj\/sfae434","article-title":"The true cost of phosphate control in chronic kidney disease","volume":"18","author":"Rodelo-Haad","year":"2025","journal-title":"Clin. Kidney Journal"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1172\/jci61405","article-title":"Fgf23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J. Clinical Investigation"},{"key":"B64","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/mnh.0000000000000900","article-title":"Kidney clearance of fibroblast growth Factor-23 in humans","volume":"32","author":"Sharma","year":"2023","journal-title":"Curr. Opinion Nephrology Hypertension"},{"key":"B65","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/jbmr.0301264","article-title":"Fgf-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J. Bone Mineral Research The Official Journal Am. Soc. Bone Mineral Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1172\/jci131190","article-title":"Glycerol-3-Phosphate is an Fgf23 regulator derived from the injured kidney","volume":"130","author":"Simic","year":"2020","journal-title":"J. Clinical Investigation"},{"key":"B67","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","article-title":"Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease","volume":"90","author":"Singh","year":"2016","journal-title":"Kidney International"},{"key":"B68","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.biocel.2017.09.009","article-title":"Fgf23 activates injury-primed renal fibroblasts via Fgfr4-Dependent signalling and enhancement of Tgf-\u0392 autoinduction","volume":"92","author":"Smith","year":"2017","journal-title":"International Journal Biochemistry & Cell Biology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/ki.2013.526","article-title":"Renal expression of Fgf23 and peripheral resistance to elevated Fgf23 in rodent models of polycystic kidney disease","volume":"85","author":"Spichtig","year":"2014","journal-title":"Kidney International"},{"key":"B70","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1525-139X.2007.00308.x","article-title":"Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease","volume":"20","author":"Stubbs","year":"2007","journal-title":"Seminars Dialysis"},{"key":"B71","first-page":"12141","article-title":"Serum fibroblast growth factor 23 for early detection of acute kidney injury in critical illness","volume":"13","author":"Sun","year":"2021","journal-title":"Am. Journal Translational Research"},{"key":"B72","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11255-021-02848-0","article-title":"Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis","volume":"54","author":"Takkavatakarn","year":"2022","journal-title":"Int. Urology Nephrology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.semnephrol.2019.10.009","article-title":"Hypoxia and endothelial dysfunction in autosomal-dominant polycystic kidney disease","volume":"39","author":"Theodorakopoulou","year":"2019","journal-title":"Seminars Nephrology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41581-019-0197-5","article-title":"The multifaceted role of iron in renal health and disease","volume":"16","author":"van Swelm","year":"2020","journal-title":"Nat. Reviews Nephrol."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11110647","article-title":"Fgf23 and phosphate-cardiovascular toxins in ckd","volume":"11","author":"Vogt","year":"2019","journal-title":"Toxins"},{"key":"B76","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5414\/cn109359","article-title":"Early postoperative measurement of fibroblast growth factor 23 predicts severe acute kidney injury in infants after cardiac surgery clinical nephrology","volume":"90","author":"Volovelsky","year":"2018","journal-title":"Clin. Nephrol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/ndt\/gfad247","article-title":"Kidney phosphate wasting predicts poor outcome in polycystic kidney disease","volume":"39","author":"Xue","year":"2024","journal-title":"Nephrol. Dialysis, Transplantation"},{"key":"B78","first-page":"443","article-title":"Arterial dysfunction in early autosomal dominant polycystic kidney disease independent of fibroblast growth factor 23","volume":"8","author":"Yildiz","year":"2014","journal-title":"Iran. Journal Kidney Diseases"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00467-022-05791-z","article-title":"Research progress of fibroblast growth factor 23 in acute kidney injury","volume":"38","author":"Zhang","year":"2023","journal-title":"Pediatr. Nephrology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.21037\/apm-21-1943","article-title":"Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Zhao","year":"2022","journal-title":"Ann. Palliative Medicine"},{"key":"B81","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000517734","article-title":"Fibroblast growth factor 23 regulation and acute kidney injury","volume":"146","author":"Zhou","year":"2022","journal-title":"Nephron"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1764206\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:33:21Z","timestamp":1771310001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1764206\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":81,"alternative-id":["10.3389\/fmolb.2026.1764206"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2026.1764206","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"article-number":"1764206"}}